[Pharmacological treatment of COPD. Where are we now?]

Arch Bronconeumol. 2010 Dec:46 Suppl 10:3-7. doi: 10.1016/S0300-2896(10)70049-1.
[Article in Spanish]

Abstract

Current clinical guidelines recommend a step-wise approach to the pharmacological treatment of chronic obstructive pulmonary disease (COPD), with drugs being added according to the severity of airflow obstruction, symptoms, and the number of acute exacerbations in patients with severe disease. However, greater knowledge of the physiopathogenesis of this disease has led to COPD being considered a heterogeneous process in which therapeutic decisions should not be based exclusively on the results of spirometry. Treatment is increasingly individualized according to the patient's characteristics. The present article reviews the scientific evidence on the aims of treatment in COPD and the benefits achieved by the various pharmacological options available.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Anti-Inflammatory Agents / therapeutic use
  • Bronchodilator Agents / therapeutic use
  • Combined Modality Therapy
  • Disease Management
  • Disease Progression
  • Exercise Tolerance
  • Humans
  • Oxygen Inhalation Therapy
  • Phosphodiesterase 4 Inhibitors / therapeutic use
  • Practice Guidelines as Topic
  • Precision Medicine
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Pulmonary Disease, Chronic Obstructive / therapy
  • Randomized Controlled Trials as Topic
  • Smoking Cessation

Substances

  • Adrenal Cortex Hormones
  • Anti-Inflammatory Agents
  • Bronchodilator Agents
  • Phosphodiesterase 4 Inhibitors